Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
BSGM - BioSig Technologies, Inc.
Market Cap 59.20M P/E - EPS this Y 74.70% Ern Qtrly Grth -
Income -18.07M Forward P/E -2.29 EPS next Y 24.00% 50D Avg Chg -34.00%
Sales 40k PEG - EPS past 5Y - 200D Avg Chg -15.00%
Dividend N/A Price/Book 26.67 EPS next 5Y - 52W High Chg -52.00%
Recommedations 2.00 Quick Ratio 0.75 Shares Outstanding 16.28M 52W Low Chg 219.00%
Insider Own 30.77% ROA -326.50% Shares Float 11.56M Beta 0.65
Inst Own 0.04% ROE -6,342.03% Shares Shorted/Prior 461.70K/0.96M Price 0.80
Gross Margin 100.00% Profit Margin - Avg. Volume 763,230 Target Price 2.50
Oper. Margin -40,707.69% Earnings Date Nov 11 Volume 397,597 Change -7.03%
Healthcare | Medical Devices | United States
About BioSig Technologies, Inc.

BioSig Technologies, Inc., a medical technology company, focuses on deciphering the body's electrical signals starting with heart rhythms. It delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines. The company's product, the PURE EP Platform, provides real-time signal visualization allowing physicians to perform targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

BioSig Technologies, Inc. News
11/13/24 BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
10/22/24 BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel
08/01/24 BioSig intends to acquire Neuro-Kinesis’ assets
07/31/24 BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation
12:57 PM BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024
06/10/24 BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer
05/30/24 BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
05/30/24 BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
05/21/24 BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders
05/03/24 BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent
04/30/24 BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
04/04/24 BioSig Engages Consulting Firm for Business Model Strategies
02/20/24 BioSig Announces Reduction of its Workforce
02/06/24 BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
01/31/24 BioSig Announces Reverse Stock Split
01/30/24 BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Jun 12 Buy 1.17 6,000 7,020 2,491,420 06/12/23
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Sep 07 Buy 0.91 7,250 6,598 1,844,354 09/08/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Sep 02 Buy 1.04 12,300 12,792 1,837,806 09/07/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Sep 01 Buy 1.0849 17,240 18,704 1,824,804 09/02/22
CHAUSSY STEVE Chief Financial Offi.. Chief Financial Officer Sep 01 Buy 1.1316 11,425 12,929 1,051,553 09/02/22
Sieckhaus John Chief Operating Offi.. Chief Operating Officer Aug 30 Buy 1.067 5,000 5,335 65,000 09/01/22
Fleming Gray Chief Commercial Off.. Chief Commercial Officer Aug 24 Buy 1.18 36,036 42,522 36,036 08/31/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Aug 29 Buy 1.08 17,850 19,278 1,807,564 08/31/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Aug 25 Buy 1.14 16,726 19,068 1,789,714 08/29/22
Sieckhaus John Chief Operating Offi.. Chief Operating Officer Aug 24 Buy 1.1347 10,000 11,347 60,000 08/25/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Aug 23 Buy 1.1 12,000 13,200 1,772,988 08/24/22
CHAUSSY STEVE Chief Financial Offi.. Chief Financial Officer Aug 22 Buy 1.127 8,000 9,016 1,040,128 08/24/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Aug 19 Buy 1 10,000 10,000 1,760,988 08/22/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Aug 17 Buy 0.92 13,100 12,052 1,750,988 08/19/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Aug 16 Buy 0.89 25,100 22,339 1,737,888 08/17/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer May 25 Buy 1.15 9,300 10,695 1,712,788 05/26/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer May 24 Buy 1.0980 8,744 9,601 1,703,488 05/25/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer May 20 Buy 1.14 15,500 17,670 1,694,744 05/24/22
LONDONER KENNETH L Chief Executive Offi.. Chief Executive Officer Sep 02 Buy 3.1 5,600 17,360 1,710,658 09/02/21
ODONNELL JEFFREY F Director Director Feb 09 Sell 5.06 105,000 531,300 151,629 02/09/21